Rouprêt Morgan, Fromont Gaëlle, Azzouzi Abdel-Rahmène, Catto Jim W, Vallancien Guy, Hamdy Freddie C, Cussenot Olivier
Department of Urology, Tenon Hospital, AP-HP, Paris, France.
Urology. 2005 Jun;65(6):1233-7. doi: 10.1016/j.urology.2005.01.019.
To establish whether high microsatellite instability (MSI) (present in almost 20% of cases) and loss of MSH2 protein expression (sometimes used to predict MSI status) are prognostic factors of overall survival for patients with invasive upper urinary tract transitional cell carcinoma (UUT-TCC). UUT-TCC has a poor prognosis (overall survival less than 50% at 5 years).
The files of 80 patients who underwent nephroureterectomy for invasive UUT-TCC (Stage pT2 or worse) between 1990 and 2002 were reviewed. The following data were collated: age at diagnosis, prior history of cancer, tobacco consumption, tumor stage and grade, and disease progression. MSI was determined by polymerase chain reaction/fragment analysis and MSH2 protein expression by immunohistochemistry on retrieved tumor tissue.
The median patient age was 71.5 years. The male/female ratio was 2.8. High MSI and loss of MSH2 expression were encountered in the tumors of 14 (17%) and 21 (26%) of the 80 patients, respectively. High MSI was significantly associated with patients with a better prognosis (Stage T2-T3N0M0; P = 0.02). The mean overall survival was 22.5 +/- 18 months (range 6 to 78). In univariate analyses, age, stage, tumor grade, high MSI, and loss of MSH2 expression were related to better overall survival (37 +/- 22 months, P = 0.003; 34 +/- 22 months, P = 0.02). Only stage, age, and high MSI were prognostic factors in a multivariate analysis (P < 0.05).
MSI and expression of MSH2 are useful prognostic factors in invasive UUT-TCC. However, other than age and stage, only MSI was an independent factor. High MSI indicates a better prognosis, especially in patients younger than 71 years with Stage T2-T3N0M0.
确定高度微卫星不稳定(MSI)(近20%的病例存在)和MSH2蛋白表达缺失(有时用于预测MSI状态)是否为浸润性上尿路移行细胞癌(UUT-TCC)患者总生存期的预后因素。UUT-TCC预后较差(5年总生存率低于50%)。
回顾了1990年至2002年间80例因浸润性UUT-TCC(pT2期或更晚期)接受肾输尿管切除术患者的病历。整理了以下数据:诊断时年龄、既往癌症史、吸烟情况、肿瘤分期和分级以及疾病进展情况。通过聚合酶链反应/片段分析确定MSI,通过对获取的肿瘤组织进行免疫组织化学检测MSH2蛋白表达。
患者中位年龄为71.5岁。男女比例为2.8:1。80例患者中,分别有14例(17%)和21例(26%)的肿瘤出现高度MSI和MSH2表达缺失。高度MSI与预后较好的患者显著相关(T2-T3N0M0期;P = 0.02)。平均总生存期为22.5±18个月(范围6至78个月)。单因素分析中,年龄、分期、肿瘤分级、高度MSI和MSH2表达缺失与较好的总生存期相关(37±22个月,P = 0.003;34±22个月,P = 0.02)。多因素分析中,只有分期、年龄和高度MSI是预后因素(P < 0.05)。
MSI和MSH2表达是浸润性UUT-TCC有用的预后因素。然而,除年龄和分期外,只有MSI是独立因素。高度MSI提示较好的预后,尤其是71岁以下T2-T3N0M0期患者